RSC Bay Area Is First in the Nation to Deploy FDA-Cleared AI for Embryo Assessment by Alife Health, Pioneering a New Standard in IVF Care
Publish Date: 2026-06-02 07:00:00
Source Domain: www.prnewswire.com
- RSC Bay Area, a leading US fertility practice, has become the first clinic in the U.S. to use Alife Health’s Embryo Predict for routine clinical IVF treatment.
- This comes days after the AI-powered embryo assessment tool received FDA clearance, marking a substantial step in U.S. reproductive medicine.
- Embryo Predict uses AI trained on thousands of embryo images to analyze blastocysts and generate a score that aids in selecting the most viable embryo for transfer, reducing subjectivity.
- The tool’s approval followed a large multi-center randomized trial, which RSC Bay Area participated in and demonstrated the tool’s effectiveness.
- The integration of Embryo Predict into RSC Bay Area’s practice was made possible through years of partnership and collaboration between RSC Bay Area’s parent network, US Fertility, and Alife Health.
- Patients at RSC Bay Area now have access to this advanced AI-assisted embryo selection as part of their standard IVF care options.
- The Embryo Predict tool has received FDA clearance in the U.S. and CE Mark in Europe, and is commercially available in the U.S., Europe, and the U.K.
- Embryo Predict complements the expertise of embryologists, providing an additional data-driven insight to support consistent, evidence-based decisions in embryo selection.
